Cleveland Clinic London and Bupa UK Insurance have expanded their healthcare partnership into cardiac care, introducing an outcome-based programme that links reimbursement to measurable improvements in patient health. The initiative represents a further move toward value-based healthcare in the UK, where providers and insurers are increasingly looking beyond procedure volumes and focusing on the results achieved for patients.
The new cardiac pilot covers electrophysiology, interventional cardiology and cardiac surgery. Under the agreement, Cleveland Clinic London’s reimbursement will be connected to patient outcomes rather than relying solely on conventional fee-for-service payments. The model is intended to encourage closer coordination across different stages of cardiac treatment while giving patients greater visibility over the quality and cost of their care.
The development comes as demand for advanced cardiovascular devices, procedures and specialist cardiac services continues to grow alongside efforts to improve clinical efficiency. By tying financial arrangements to measurable outcomes, the programme could provide a framework for insurers and private healthcare providers seeking to balance access to advanced treatment with greater accountability for results.
The partnership builds on an earlier collaboration between the two organisations in arthroplasty, launched two years ago. According to the organisations, that programme delivered an average 63% improvement in patient-reported outcome scores without significant clinical complications. The results have provided a foundation for extending the approach into a more complex area of healthcare.
Cleveland Clinic London and Bupa Extend Value-Based Care Into Cardiology
Cardiac treatment can involve multiple specialists, diagnostic assessments and interventions, making coordination particularly important. The new programme is designed to bring these services under an outcome-focused reimbursement framework covering several major areas of cardiovascular care.
Electrophysiology procedures are used to diagnose and treat abnormal heart rhythms, while interventional cardiology encompasses minimally invasive procedures for conditions affecting the heart and blood vessels. Cardiac surgery covers more complex surgical interventions. Bringing these areas into one programme allows the organisations to assess patient outcomes across a broader portion of the treatment pathway.
The financial structure is a significant part of the initiative. Instead of reimbursement being determined primarily by the number or type of services delivered, Cleveland Clinic London’s payment will be linked to measurable health improvements. The approach is intended to encourage providers to focus on whether patients achieve better results and maintain those improvements over time.
For Bupa members, the agreement also retains a no-shortfall guarantee covering consultant fees. This means eligible patients are protected from unexpected additional charges associated with consultant treatment, addressing one of the concerns that can accompany private healthcare.
Bernard Prendergast, chair of Cardiology at Cleveland Clinic London, said the organisations wanted to extend their focus on transparent and high-quality care into cardiac services. The partnership, he said, could help deliver improvements that affect both longevity and quality of life.
The move is also notable from a commercial perspective. Outcome-based healthcare models have gained attention as healthcare systems face pressure from rising costs, ageing populations and growing demand for specialist treatment. For insurers, linking payment to outcomes can create incentives to reduce avoidable complications and improve the overall patient journey.
For hospitals, meanwhile, successful outcome-based arrangements can provide a way to demonstrate the value of specialist expertise and advanced treatment capabilities. The Cleveland Clinic London and Bupa model will therefore be closely watched as private healthcare providers in the UK explore alternative approaches to reimbursement.
The expansion also reflects a broader shift in how healthcare organisations assess performance. Patient-reported outcomes, clinical complications and longer-term recovery are becoming increasingly important alongside traditional measures such as procedure volumes and hospital activity.
King Edward VII’s Hospital Adds Aquablation for Prostate Treatment
Elsewhere in London’s private healthcare market, King Edward VII’s Hospital has expanded its urological treatment offering with the introduction of Aquablation therapy for men with benign prostatic hyperplasia, or BPH.
The hospital has also recently completed its first procedure using Rezūm water vapour therapy, giving patients additional minimally invasive options for managing an enlarged prostate.
Aquablation uses the AquaBeam Robotic System to remove excess prostate tissue that can obstruct the flow of urine. The procedure combines real-time ultrasound imaging with a computer-controlled waterjet, allowing clinicians to identify and target tissue while avoiding the use of heat during tissue removal.
The heat-free approach is intended to reduce thermal injury to surrounding structures. The technology also uses automated waterjet delivery, giving clinicians greater control over the area being treated.
BPH is a common condition among older men and can cause symptoms including frequent urination, difficulty starting urination and incomplete emptying of the bladder. While medication can manage symptoms for some patients, others require a procedure when symptoms become more severe or do not respond adequately to drug treatment.
Traditional surgical approaches such as transurethral resection of the prostate, commonly known as TURP, remain established treatments for BPH. However, the availability of newer technologies is creating additional options for patients who are seeking less invasive approaches.
Richard Hindley, consultant urologist at King Edward VII’s Hospital, said Aquablation could offer patients reassurance by reducing the risk of certain long-term complications associated with conventional surgical treatment.
The introduction of Aquablation and Rezūm also demonstrates the growing emphasis on treatment options designed to minimise disruption and preserve quality of life. For hospitals, adding these technologies can strengthen specialist service lines while giving clinicians greater flexibility when selecting procedures for individual patients.
Taken together, the developments at Cleveland Clinic London, Bupa UK Insurance and King Edward VII’s Hospital highlight two important trends in private healthcare. The first is the shift toward measuring value through patient outcomes rather than activity alone. The second is the continued adoption of technologies that aim to deliver targeted treatment while reducing the burden of invasive procedures.
As healthcare providers face increasing pressure to demonstrate clinical value, both trends are likely to remain central to investment and service development across the UK private healthcare market.
